Literature DB >> 12373488

A prospective study of hemodialysis access-related bacterial infections.

Ibrahiem Saeed Abdulrahman1, Samir H Al-Mueilo, Huda A Bokhary, Gani O A Ladipo, Abdulla Al-Rubaish.   

Abstract

The objective of this study was to describe hemodialysis vascular-access related infections that occurred in hemodialysis patients over an 18-month period. The study is a prospective descriptive analysis of incidence infection rates in a hemodialysis unit in a tertiary-care medical center. Prospective surveillance for hemodialysis vascular access-related infection was performed for all patients undergoing hemodialysis from November 1999 through April 2001 at King Fahd Hospital of King Faisal University, Al-Khobar, Saudi Arabia. The total number of dialysis sessions was calculated. The type of vascular access was noted. Cultures were obtained and all infections were recorded and infection rates were calculated. There were 9627 hemodialysis sessions (5437 via permanent fistulae or grafts, 2409 via temporary central catheters, and 1781 via permanent tunneled catheters) during the 18-month study period. We identified a total of 109 infections, for a rate of 11.32/1000 dialysis sessions (ds). Of the 109, 23 involved permanent fistulae or grafts (4.23/1000 ds); 18 involved permanent-tunneled central catheter infections (10.1/1000 ds); and 68 involved temporary-catheter infections (28.23/1000 ds). There were 38 bloodstream infections (3.95/1000 ds) and 34 episodes of clinical sepsis (3.53/1000 ds). Seventy-one vascular access infections without bacteremia were identified (7.38/1000 ds), including 16 permanent-fistulae or graft infections (2.94/1000 ds), 7 permanent-tunneled central catheter infections (3.93/1000 ds), and 48 temporary-catheter infections (19.92/1000 ds). Staphylococcal organisms were responsible for 77% of the infections, with Staphylococcus epidermidis being the strain most commonly implicated. Gram-negative organisms were responsible for 23% of the infections. In conclusion, infection rates were highest in hemodialysis patients with temporary vascular access, compared with rates in those with permanent arteriovenous fistulae and synthetic grafts. Most of the bacterial organisms isolated from the vascular access sites were gram-positive cocci, with S. epidermidis accounting for 50% of the organisms. The rate of infection with gram-negative bacilli was higher than in other reports. Our greater dependence on central venous catheters, due to local factors, coupled with the immune-compromising comorbid conditions of our patients, may be contributory to the pattern of infection reported. Delays in the creation of vascular grafts for hemodialysis access should be avoided.

Entities:  

Mesh:

Year:  2002        PMID: 12373488     DOI: 10.1007/s10156-002-0184-8

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  17 in total

1.  Vascular access infections: epidemiology, diagnosis, and management.

Authors:  Jacob A Akoh
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

2.  A crossover intervention trial evaluating the efficacy of a chlorhexidine-impregnated sponge in reducing catheter-related bloodstream infections among patients undergoing hemodialysis.

Authors:  Bernard C Camins; Amy M Richmond; Kathrin L Dyer; Heather N Zimmerman; Daniel W Coyne; Marcos Rothstein; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

3.  Value of superficial cultures for prediction of catheter-related bloodstream infection in long-term catheters: a prospective study.

Authors:  M Guembe; P Martín-Rabadán; A Echenagusia; F Camúñez; G Rodríguez-Rosales; G Simó; M Echenagusia; E Bouza
Journal:  J Clin Microbiol       Date:  2013-07-12       Impact factor: 5.948

4.  Vascular access port implantation and serial blood sampling in a Gottingen minipig (Sus scrofa domestica) model of acute radiation injury.

Authors:  Maria Moroni; Thea V Coolbaugh; Jennifer M Mitchell; Eric Lombardini; Krinon D Moccia; Larry J Shelton; Vitaly Nagy; Mark H Whitnall
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-01       Impact factor: 1.232

5.  Infections in the survivors of out-of-hospital cardiac arrest in the first 7 days.

Authors:  Min-Shan Tsai; Wen-Chu Chiang; Chien-Chang Lee; Cheng-Chun Hsieh; Patrick Chow-In Ko; Chiung-Yuan Hsu; Chan-Ping Su; Shey-Ying Chen; Wei-Tein Chang; Ang Yuan; Matthew Huei-Ming Ma; Shyr-Chyr Chen; Wen-Jone Chen
Journal:  Intensive Care Med       Date:  2005-04-01       Impact factor: 17.440

6.  Central venous catheter-associated bloodstream infections in hemodialysis patients: Another patient safety bundle?

Authors:  B Lynn Johnston; John M Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-03       Impact factor: 2.471

7.  Neuraminidase produces a decrease of adherence of slime-forming Staphylococcus aureus to gelatin-impregnated polyester fiber graft fabric: an experimental study.

Authors:  Mustafa Sacar; Gokhan Onem; Ahmet Baltalarli; Suzan Sacar; Huseyin Turgut; Ibrahim Goksin; Vefa Ozcan; Serhan Sakarya
Journal:  J Artif Organs       Date:  2007-09-20       Impact factor: 1.731

8.  Blood Loss through AV Fistula: A Case Report and Literature Review.

Authors:  Fahad Saeed; Nadia Kousar; Ramapriya Sinnakirouchenan; Vijaya S Ramalingam; Philip B Johnson; Jean L Holley
Journal:  Int J Nephrol       Date:  2011-05-30

9.  Incidence and clinical implication of nosocomial infections associated with implantable biomaterials - catheters, ventilator-associated pneumonia, urinary tract infections.

Authors:  Josef Peter Guggenbichler; Ojan Assadian; Michael Boeswald; Axel Kramer
Journal:  GMS Krankenhhyg Interdiszip       Date:  2011-12-15

10.  Systemic and local antibiotic prophylaxis in the prevention of Staphylococcus epidermidis graft infection.

Authors:  Huseyin Turgut; Suzan Sacar; Ilknur Kaleli; Mustafa Sacar; Ibrahim Goksin; Semra Toprak; Ali Asan; Nural Cevahir; Koray Tekin; Ahmet Baltalarli
Journal:  BMC Infect Dis       Date:  2005-10-21       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.